World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 5
Page: 526-538

A REVIEW ON BONE CANCER DIAGNOSIS AND TREATMENT

Jyoti Burnwal*[1], Rakesh Kumar Sahu[2], Piyush Kumar Pathak[3], Ritu Raj[4], Sudhir Singh[5], Kundan Kumar[6], Ankit Kumar[7]

[1,2]Assistant Professor, Mahadeva Lal Schroff College of Pharmacy Aurangabad Bihar-824102.

[3-7]B. Pharm Final Year Students, Mahadeva Lal Schroff College of Pharmacy Aurangabad, Bihar-824102.

Article Received: 17 March 2026 | | ***Article Revised: 8 April 2026*** | | ***Article Accepted: 28 April 2026***

***Corresponding Author: Jyoti Burnwal**
Assistant Professor, Mahadeva Lal Schroff College of Pharmacy Aurangabad Bihar-824102.
DOI: https://doi.org/10.5281/zenodo.19997469

How to cite this Article: Jyoti Burnwal, Rakesh Kumar Sahu, Piyush Kumar Pathak, Ritu Raj, Sudhir Singh, Kundan Kumar, Ankit Kumar (2026) A REVIEW ON BONE CANCER DIAGNOSIS AND TREATMENT. World Journal of Pharmaceutical Science and Research, 5(5), 526-538.

ABSTRACT

Primary bone cancers, predominantly comprising osteosarcoma, Ewing sarcoma, and chondrosarcoma, represent a rare yet clinically formidable group of malignancies accounting for less than 1% of all cancer diagnoses. Despite their low incidence, these tumors are characterized by significant morbidity and high mortality rates, largely driven by diagnostic delays. Such delays often stem from a combination of late patient presentation, non-specific symptoms that masquerade as common musculoskeletal injuries, and a generally low index of clinical suspicion among primary care providers. Plain radiography remains the gold-standard initial diagnostic tool, where any suspicion of malignancy necessitates immediate referral to specialized centers for multidisciplinary intervention. Current therapeutic protocols—incorporating neoadjuvant and adjuvant chemotherapy alongside advanced surgical techniques have revolutionized outcomes for localized disease, achieving survival rates of approximately 80% and enabling limb-salvage in 90% to 95% of patients. However, the prognosis remains heavily contingent on the presence of metastasis, particularly in the pediatric and adolescent populations most affected by osteosarcoma and Ewing sarcoma, where five-year survival drops to 20%–30%. In contrast, chondrosarcoma primarily affects adults over 40 and typically carries a more favorable prognosis due to its presentation as a low-grade lesion. This abstract emphasizes that improving the diagnostic window and maintaining high radiographic vigilance are essential for optimizing survival and functional outcomes.

KEYWORDS: Osteosarcoma, Chondrosarcoma, Chemotherapy.

1. NTRODUCTION

The skeletal system serves as a frequent site for oncological activity, yet the vast majority of malignancies found within bone do not originate from the osseous tissue itself. Most commonly, skeletal bones host secondary or metastatic

malignancies, serving as a fertile "soil" for cells migrating from primary sites such as the breast, lungs, prostate, kidneys, or thyroid. Furthermore, the bone marrow frequently acts as the nidus for hematologic malignancies, including multiple myeloma, lymphoma, and leukemia. In these instances, while the clinical manifestation occurs within the bone, the pathological cells retain the characteristics of their non-bony origins.[1]

Bone cancer is still a serious medical issue. Tumor excision is the most often used therapeutic therapy approach today. Although it is mostly successful, there are a number of possible drawbacks, including the need for several surgeries, extended hospital stays, and the possibility of recurrence due to insufficient cancer cell removal. Malignant bone tumors, often known as bone cancer, are tumors that develop in the bone or its supporting tissues. It is separated into primary bone cancer and bone metastases. Changes in cellular DNA that result in unchecked cell division are the cause of cancer.[2] In 2020 alone, there were 18.1 million instances of cancer globally, according to the World Cancer Research Fund. Since 1995, the annual death rate from cancer has been declining because of improvements in early identification and treatment. However, in 2020 and 2021, cancer was the second leading cause of death in the US and still killed more people than COVID-19. One important element that may contribute to the failure of cancer therapies is the existence of cancer stem cells (CSCs).[3] Because bone cancer significantly impairs a patient's quality of life, a multidisciplinary approach is essential to ensuring optimal care. An uncommon but dangerous kind of cancer that arises in bone tissue is called bone cancer. The primary cause of cancer is a loss of genomic stability. Certain DNA damaging chemicals from carcinogens primarily change the stability of cells' genomes. Tumors of the soft tissues and bones are conditions that pose a major threat to human life and health.[4] Primary malignant bone tumors have increasingly become more common in recent years. Most primary malignant bone tumors, such as osteosarcoma, Ewing sarcoma, chondrosarcoma, malignant fibrous histiocytoma, chordoma, and others, occur in adolescents and middleaged adults between the ages of 10 and 30.

In contrast, primary bone cancers—specifically osteosarcoma, Ewing sarcoma, and chondrosarcoma—are true malignancies of the bone, arising directly from mesenchymal cell lines.[5] Although these primary tumors are exceptionally rare, accounting for less than 1% of all cancer diagnoses annually, they represent a significant clinical burden characterized by high morbidity and mortality. Their rarity often leads to a "diagnostic gap," where early symptoms are misidentified as benign musculoskeletal trauma, delaying critical intervention.

The management of these cancers has evolved from radical amputation to sophisticated multidisciplinary protocols.[6]

The integration of neoadjuvant chemotherapy and precise surgical resection has significantly improved the five-year survival rate for localized disease to nearly 80%. However, the prognosis remains heavily guarded for patients presenting with metastatic spread, where survival rates plummet to 20%–30%. This article provides a comprehensive review of the unique pathophysiology, diagnostic hallmarks, and evolving treatment landscapes for these three primary bone malignancies, emphasizing the necessity of early radiographic suspicion and specialized multidisciplinary care.

Bone cancer is mainly diagnosed through imaging examinations, including computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and X-ray. For better diagnosis, invasive needle−/surgical-based biopsies are also applied. Once the location, size, stages (0 to IV) of bone tumors, and possible metastasis are determined, the treatment modality (i.e., surgery, chemotherapy, immunotherapy, and radiotherapy) is applied. However, even after a course of rigorous treatment, untouched remaining cancerous cells might progress

resulting in relapses of the disease. Conventional chemotherapy treatments are often associated with some issues, including the occurrence of side effects and the development of resistant mechanisms by cancer cells. Such issues may fail the treatment strategy. Therefore, to tackle bone cancers, advanced DDSs need to be developed. Schematically represents bone sericulture, bone tissue microenvironment, and cancer development together with possible treatment with multifunctional NSs, including organic, inorganic, and hybrid NSs. Given the complex structure of the bone tissue, an ideal NS should be able to accumulate in the bone TME and actively target the diseased cells. Such NSs should result in markedly reduced side effects in healthy while providing maximal impacts on the targeted OS with substantially improved impacts on cancer cells.



Figure 1: Schematic representation of bone tissue anatomy and tumor microenvironment (TME). (A) The anatomy and microstructure of the femur bone. (B) Targeted delivery of NPs to bone TME.

1.1 The Landscape of Skeletal Malignancy

The skeletal system is a dynamic tissue that frequently serves as a sanctuary or a target for various oncological processes. To understand primary bone cancer, one must first navigate the broader landscape of skeletal involvement, which is categorized primarily by the biological origin of the malignant cells.[7]

Taxonomic Classification of Bone-Associated Malignancies

The distinction between these categories is critical; it dictates the entire therapeutic trajectory, from the choice of systemic agents to the necessity of orthopedic surgical intervention.

Table 1: Comparative Classification of Cancers Found in Bone

Category	Source of Malignancy	Common Primary Sites	Primary Cell Type involved
Primary Bone Cancer (Sarcoma)	Originates within the bone or cartilage tissue itself.	Bone (e.g., Femur, Tibia, Pelvis).	Mesenchymal (Osteoblasts, Chondroblasts).
Metastatic (Secondary) Bone Cancer	Spreads to the bone from a distant organ via the circulatory or lymphatic system.	Breast, Prostate, Lung, Renal, and Thyroid.	Epithelial (Cells from the primary organ).
Hematologic Bone Malignancy	Originates in the bone marrow (the blood-forming tissue).	Bone Marrow (systemic).	Plasma cells, Leukocytes, Lymphocytes.

The "Seed and Soil" Hypothesis in Bone Metastasis

The prevalence of metastatic (secondary) bone cancer is explained by the "Seed and Soil" theory. Bone tissue is a rich reservoir of growth factors (such as TGF-β and IGFs) stored within the mineralized matrix. When metastatic "seeds" from the breast or prostate land in the bone "soil," they release cytokines that stimulate osteoclasts. This bone resorption releases more growth factors, creating a vicious cycle of tumor growth and skeletal destruction.[8]

Table 2: Radiographic and Clinical Features of Bone Involvement.

Feature	Primary Bone Sarcomas	Metastatic Bone Disease	Hematologic (Myeloma/Leukemia)
Typical Age	10–25 years (except Chondrosarcoma)	> 50 years	> 60 years
Common Sites	Metaphysis of long bones	Axial skeleton (Spine, Pelvis, Ribs)	Skull, Spine, and Long bones
Radiographic Sign	Codman triangle, Sunburst pattern	Lytic "holes" or Sclerotic "spots"	"Punched-out" lytic lesions
Systemic Symptoms	Localized pain, occasional fever	Weight loss, hypercalcemia	Anemia, renal failure, infections

1.2. Primary Bone Cancers

Primary bone cancers, or bone sarcomas, are defined by their origin within the mesenchymal tissues of the skeletal system. While they are statistically rare, their clinical impact is profound because they disrupt the structural integrity of the body and often affect patients during their most active years of development.

1.2.1 Osteosarcoma: The Bone-Forming Malignancy

Osteosarcoma is the most prevalent primary bone cancer, characterized by the direct production of osteoid (immature bone matrix) by malignant cells.

- Demographics: It follows a bimodal distribution, primarily peaking during the adolescent growth spurt (10–25 years) and again in older adults (usually secondary to Paget's disease).
- Anatomical Predilection: It predominantly targets the metaphysis of long bones—the area of highest cellular turnover. Approximately 50% of cases occur around the knee (distal femur or proximal tibia).
- Pathophysiology: The tumor replaces normal bone with a disorganized, "moth-eaten" matrix. As it expands, it breaks through the cortex and lifts the periosteum, creating the radiographic "Sunburst" appearance.

1.2.2 Ewing Sarcoma: The Neuroectodermal Challenge

Ewing sarcoma is the second most common bone cancer in children and young adults. Unlike osteosarcoma, it is characterized by small, round, blue cells and is often associated with a specific genetic translocation.[9]

- Anatomical Predilection: While it can affect any bone, it is frequently found in the diaphysis (shaft) of long bones and flat bones like the pelvis and ribs.[10]
- Clinical Presentation: It often mimics an infection (osteomyelitis), presenting with localized pain, swelling, and systemic signs like fever or elevated white blood cell counts.
- Radiographic Hallmark: It often produces an "onion-skin" periosteal reaction due to successive layers of new bone formation as the tumor pushes outward.[11,12]

1.2.3 Chondrosarcoma: The Cartilage-Origin Tumor

Chondrosarcoma is distinct from the other two because it arises from chondrocytes (cartilage cells). It is the rarest of the three and behaves very differently in a clinical setting.[13]

- Demographics: It primarily affects adults, typically those over the age of 40.
- Biological Behavior: These tumors are often slow-growing and are notorious for being resistant to standard chemotherapy and radiation.
- Management: Because of its chemo-resistance, the primary treatment is wide surgical excision. Survival rates are generally higher because many chondrosarcomas are low-grade (less aggressive) at the time of discovery.[14,15]

Comparative Analysis of Primary Bone Sarcomas

The following table summarizes the core differences that define these three malignancies within the skeletal landscape.[16]

Table 3: Comparative Profiles of Primary Bone Sarcomas.

Feature	Osteosarcoma	Ewing Sarcoma	Chondrosarcoma
Cell of Origin	Osteoblast (Bone-forming)	Mesenchymal/Neuroectodermal	Chondrocyte (Cartilage)
Peak Age	10–25 years	5–20 years	40–70 years
Common Site	Metaphysis (Knee, Humerus)	Diaphysis (Shaft), Pelvis	Pelvis, Shoulder, Ribs
Growth Rate	Rapid / Aggressive	Rapid / Highly Aggressive	Variable (Often Slow)
Chemo-Sensitivity	High	High	Very Low
Key X-ray Sign	Sunburst / Codman Triangle	"Onion-skin" appearance	Popcorn-like calcification

1.2.4 The Shared Threat: Metastatic Potential

Despite their different origins, all three primary bone cancers share a high affinity for hematogenous spread (spread via the blood). The lungs are the most common site of metastasis for all three.[17] This shared trait is why systemic evaluation (CT scans of the chest) and multidisciplinary treatment are mandatory components of the diagnostic workup for any suspected primary bone malignancy.

2. The Diagnostic Challenge: The "Clinical Masquerade"

The diagnostic journey for a primary bone cancer patient is often a race against time, yet the "finish line" is frequently obscured by the subtle and deceptive nature of early symptoms.[18] On average, there is a delay of 15 to 25 weeks from the onset of symptoms to a definitive diagnosis, a window during which a localized tumor can progress to metastatic disease.

2.1 Factors Contributing to Diagnostic Delay

The "masquerade" is driven by three primary factors: the age of the patient, the nature of the symptoms, and the rarity of the disease.[19]

- Symptom Mimicry: The hallmark of bone cancer is localized pain and swelling. In adolescents—the primary demographic for osteosarcoma and Ewing sarcoma—these symptoms are almost indistinguishable from common sports injuries, ligamentous strains, or "growing pains."
- Low Clinical Index of Suspicion: Because primary bone cancers account for less than 1% of annual diagnoses, general practitioners and pediatricians rarely encounter them. Common pathologies are naturally prioritized in the differential diagnosis.[20]
- Intermittent Presentation: Early bone pain is often dull and comes and goes, leading patients and parents to believe the "injury" is healing, thereby delaying the decision to seek medical imaging.

2.2 Red Flags: Distinguishing Malignancy from Injury

To unmask the malignancy, clinicians must look for "red flags" that deviate from standard musculoskeletal trauma. The most significant indicator is nocturnal pain—pain that wakes the patient from sleep or is worse at rest, which is rarely seen in simple mechanical injuries.

Table 4: Differential Diagnosis: Bone Cancer vs. Common Injuries.

Symptom	Musculoskeletal Injury (Sprain/Strain)	Primary Bone Cancer (Sarcoma)
Pain Pattern	Decreases with rest; improves over days.	Persistent; worse at night or at rest.
Response to Activity	Pain occurs *during* activity.	Pain is independent of activity level.
Swelling	Immediate; usually resolves with R.I.C.E.	Gradual; persistent and progressive.
Systemic Signs	None.	Possible fever, weight loss, fatigue (Ewing).
Physical Exam	Clear point tenderness or joint laxity.	Palpable, firm, non-mobile mass.

2.3 The Diagnostic Pipeline

The "Clinical Masquerade" ends when high-quality imaging is performed. The transition from a "sore leg" to a suspected malignancy follows a specific hierarchy of evidence.[21]

Table 5: The Diagnostic Hierarchy for Bone Malignancy.

Stage	Modality	Clinical Goal
Screening	Plain Radiography (X-ray)	Detect periosteal reactions (Sunburst/Codman's).
Staging (Local)	MRI with Contrast	Define soft tissue involvement and marrow extension.
Staging (Systemic)	CT Chest / PET Scan	Identify pulmonary or distant skeletal metastasis.
Confirmation	Core Needle Biopsy	Histological and molecular identification.

2.4 The Risk of "Biopsy Contamination"

A critical component of the diagnostic challenge is the management of the biopsy. If a biopsy is performed by a surgeon not specialized in oncology, they may use an approach that contaminates multiple muscular compartments.[22]

In the "masquerade" of bone cancer, an improper biopsy can turn a case that could have been saved with limb-salvage surgery into one that requires mandatory amputation to ensure clear margins.

3. Treatment Paradigms in Primary Bone Cancer

Modern management is built upon the "Standard of Care" (SOC) triad: Systemic Control (Chemotherapy), Local Control (Surgery), and Functional Rehabilitation.

3.1 Systemic Therapy: The Role of Chemotherapy

The integration of multi-agent chemotherapy into the treatment of bone sarcomas is considered one of the greatest successes in modern oncology. Prior to the 1970s, treatment was limited to surgery alone, resulting in a 5-year survival rate of less than 20% due to rapid pulmonary relapse. Today, systemic therapy is the cornerstone of curative intent.

3.1.1 Neoadjuvant (Pre-operative) Chemotherapy

Administered typically for 8 to 12 weeks following a diagnostic biopsy but prior to definitive surgical resection.

- Tumor Consolidation: Chemotherapy induces tumor necrosis, which often leads to the formation of a fibrous "pseudocapsule." This makes the tumor more distinct from surrounding neurovascular structures, facilitating limb-salvage surgery.
- Early Micrometastatic Control: By treating the whole body immediately, clinicians target "skip lesions" and circulating tumor cells that would otherwise colonize the lungs during the surgical recovery period.
- In-Vivo Sensitivity Testing: Perhaps most importantly, the surgical specimen's response to neoadjuvant therapy provides a "biological readout" of the tumor's sensitivity to the drugs.[23]

3.1.2 The Huvos Grading System (Histologic Response)

After the tumor is surgically removed, a pathologist calculates the percentage of cell death (necrosis). This is the most significant prognostic indicator in osteosarcoma and Ewing sarcoma.[24]

Table 6: Huvos Grading for Chemotherapeutic Response.

Grade	Necrosis Percentage	Clinical Interpretation	5-Year Survival (Est.)
Grade I	< 50% Necrosis	Poor Responder	~30% - 50%
Grade II	50% - 90% Necrosis	Partial Responder	Variable
Grade III	90% - 99% Necrosis	**Good Responder**	~75% - 85%
Grade IV	100% Necrosis	**Complete Responder**	> 90%

3.1.3 Standard Chemotherapeutic Protocols

The pharmacological choice depends heavily on the specific histological type of the primary tumor.

The MAP Regimen (Osteosarcoma)

The "MAP" protocol is the global standard for osteosarcoma and involves high-dose cycles of:

1. Methotrexate (High-dose): Inhibits dihydrofolate reductase, halting DNA synthesis.
2. Adriamycin (Doxorubicin): An anthracycline that intercalates DNA and inhibits topoisomerase II.
3. Platinum (Cisplatin): An alkylating-like agent that creates DNA cross-links, triggering apoptosis.
4. Ewing sarcoma requires a more intensive, alternating 5-drug protocol:

- VDC: Vincristine, Doxorubicin, and Cyclophosphamide.
- IE: Ifosfamide and Etoposide.

  Note: These cycles are often compressed (dose-dense therapy) to every 2 weeks to prevent tumor regrowth between rounds.

3.1.4 Adjuvant (Post-operative) Chemotherapy

Following surgery, systemic therapy continues for 6 to 10 months.

- Poor Responders (Huvos I/II): If the pathology shows poor necrosis, oncologists may "salvage" the treatment by switching to second-line agents (e.g., Ifosfamide/Etoposide for osteosarcoma) to overcome drug resistance.

- Good Responders (Huvos III/IV): The patient continues the original regimen to ensure any remaining dormant cells are eradicated.

3.1.5 Pharmacological Challenges and Toxicity

Given the high doses required to penetrate mineralized bone, the side-effect profile is significant and requires intensive hospital monitoring:

- Nephrotoxicity: High-dose Methotrexate and Cisplatin require aggressive hydration to prevent renal failure.
- Cardiotoxicity: Doxorubicin has a cumulative lifetime dose limit due to the risk of irreversible cardiomyopathy.
- Myelosuppression: Patients frequently require G-CSF (growth factors) or blood transfusions due to severe drops in white blood cell and platelet counts.

Unlike Osteosarcoma and Ewing Sarcoma, Chondrosarcoma is largely chemoresistant. This is attributed to its low vascularity, slow mitotic rate, and the presence of multidrug-resistance (MDR1) gene expression, making surgery the only viable primary treatment.[25,26]

3.2 Local Control: Surgical Principles and Limb-Salvage

Historically, primary bone cancer was managed with immediate amputation. Today, due to advancements in imaging and neoadjuvant chemotherapy, limb-salvage surgery (LSS) is achievable in over 90% of cases. Success depends on the ability to achieve oncological safety (removing the cancer) without sacrificing the limb's neurovascular integrity.

3.2.1 The Enneking Principles of Surgical Margins

The "Enneking Classification" is the gold standard used by orthopedic oncologists to define the relationship between the surgical plane and the tumor. Achieving a "Wide" margin is the primary objective for sarcomas.

Table 7: Surgical Margin Definitions in Bone Oncology.

Margin Type	Description	Risk of Local Recurrence
Intralesional	The surgical plane passes *through* the tumor (e.g., debulking).	Very High (Virtually 100%)
Marginal	Dissection occurs through the "pseudocapsule" or reactive zone.	High (Likely microscopic spread)
Wide	The tumor is removed in one piece, covered by a continuous cuff of healthy tissue.	Low (Current Standard of Care)
Radical	Removal of the entire anatomical compartment (e.g., the whole femur).	Minimal, but often unnecessary today.

3.2.2 Reconstruction Techniques in Limb-Salvage

Once the diseased bone and surrounding tissue are resected, the "skeletal defect" must be reconstructed. The choice depends on the patient's age, activity level, and the location of the tumor.

A. Endoprosthetic Replacement (Mega-prosthesis)

The most common method involves replacing the bone and joint with a modular metal implant, usually made of titanium or cobalt-chromium.

- Pros: Allows for immediate weight-bearing and faster rehabilitation.
- Cons: Implants have a finite lifespan (15–20 years) and may require "revision" surgery, especially in younger patients.

B. Biological Reconstruction (Allografts and Autografts)

Uses human bone (either from a bone bank—allograft—or the patient's own non-essential bone—autograft) to fill the gap.

- Pros: If successful, the bone incorporates into the body, providing a permanent, living solution.
- Cons: High risk of non-union (the bones failing to fuse), infection, or fracture during the long healing process.

C. Expandable "Growing" Prosthesis

Specifically designed for skeletally immature children. These implants can be lengthened non-invasively using external magnets as the child grows, preventing limb-length discrepancy without requiring repeated surgeries.

3.2.3 Special Surgical Procedures: Rotationplasty

1. In cases where a tumor is located near the knee and a standard limb-salvage is not possible, Rotationplasty (Van Nes Procedure) is a unique alternative to full amputation.
2. The middle section of the leg (including the knee) is removed.
3. The lower leg and foot are rotated 180 degrees and reattached to the thigh.
4. The ankle joint then functions as a new knee joint, allowing the patient to use a below-the-knee prosthesis with far greater mobility and control than a traditional above-the-knee amputation.

3.2.4 Challenges to Local Control

Despite surgical precision, several factors can compromise the success of local control:

- Pathological Fracture: If the bone breaks through the tumor site before surgery, malignant cells may spill into the surrounding soft tissue, significantly increasing the risk of recurrence.
- Biopsy Tract Contamination: The skin incision and path used for the initial biopsy must be completely excised during the final surgery. If the biopsy was placed incorrectly (e.g., through a different muscle compartment), it may force a more radical amputation.
- Neurovascular Involvement: If the tumor encases the major sciatic nerve or femoral artery, salvage may be impossible, as the resulting limb would be paralyzed or lack blood flow.

Table 8: Comparison of Functional Outcomes.

Procedure	Functional Capacity	Long-term Complications
Limb-Salvage	High (Near-normal walking)	Implant loosening, infection.
Rotationplasty	Excellent (Running/Sports)	Psychological adjustment to appearance.
Amputation	Moderate (Prosthesis dependent)	Phantom limb pain, high energy cost of walking.

3.3 Disease-Specific Treatment Nuances

Because primary bone cancers are histologically diverse, a "one size fits all" approach is insufficient. The sensitivity of the tumor to radiation and chemotherapy is the primary driver of the treatment sequence.

3.3.1 Osteosarcoma: The Chemosurgical Standard

Osteosarcoma is a highly aggressive, bone-forming malignancy that requires a rigid adherence to the "Sandwich" protocol: Pre-operative chemotherapy, Radical Surgery, and Post-operative chemotherapy.

- Radiotherapy Resistance: Osteosarcoma is notoriously radioresistant. Standard external beam radiation is rarely used as a primary treatment because the doses required to kill osteosarcoma cells would cause catastrophic

damage to surrounding healthy tissue.

- The MAP Standard: As previously detailed, the MAP regimen (Methotrexate, Adriamycin, Cisplatin) is the cornerstone.
- Metastasectomy: Osteosarcoma has a unique "pulmonary tropism" (affinity for the lungs). If a patient develops isolated lung nodules, aggressive surgical removal of these nodules (pulmonary metastasectomy) can still lead to a cure, which is a rare possibility in other types of cancer.[27]

3.3.2 Ewing Sarcoma: The Radiosensitive Exception

Ewing sarcoma is distinct because it is a "small round blue cell" tumor. Its lack of a dense, mineralized matrix makes it significantly more vulnerable to non-surgical interventions.

- High Radiosensitivity: Unlike osteosarcoma, Ewing sarcoma responds exceptionally well to radiation. This makes Radiotherapy (RT) a viable alternative for "local control" in anatomically challenging areas where surgery would be morbid, such as the pelvis, sacrum, or skull base.
- Dose-Dense Protocols: The standard of care involves the VDC-IE regimen. Recent clinical trials (like AEWS1031) have shown that "compressing" these treatments into shorter intervals (every 2 weeks instead of 3) significantly improves survival.
- Systemic Dominance: Because Ewing sarcoma is considered a systemic disease from the outset, chemotherapy duration is often longer than that for osteosarcoma to ensure the eradication of all neural-origin malignant cells.[28,29]

3.3.3 Chondrosarcoma: The Surgical Fortress

Chondrosarcoma represents the greatest challenge for medical oncologists because it is largely a surgical-only disease.[30]

- Double Resistance: Chondrosarcomas are both chemoresistant and radioresistant. This is due to several biological factors:
- Low Vascularity: The cartilage-like matrix has few blood vessels, preventing chemotherapy from reaching the tumor cells.
- Slow Cell Cycle: Traditional chemotherapy targets rapidly dividing cells; many chondrosarcomas grow too slowly for these drugs to be effective.
- MDR1 Expression: These tumors often overexpress "Multi-Drug Resistance" proteins that pump chemotherapy out of the cells.
- Wide Excision is Mandatory: Since no "backup" systemic therapy exists, the surgeon must achieve an impeccable Wide Margin on the first attempt.[31]
- Proton Beam Therapy: For inoperable chondrosarcomas (such as those at the base of the skull), specialized Proton Beam or Carbon Ion therapy is used, as these can deliver higher, more targeted doses than standard X-ray radiation.

3.3.4 Comparative Summary of Modality Sensitivity

Table 9: Treatment Modality Sensitivity by Tumor Type.

Modality	Osteosarcoma	Ewing Sarcoma	Chondrosarcoma
Chemotherapy	Highly Sensitive	Extremely Sensitive	Highly Resistant
Radiation Therapy	Resistant	Highly Sensitive	Resistant
Surgery	Mandatory (Limb-Salvage)	Optional but Preferred	**Primary/Only Cure**
Key Drug Goal	Necrosis > 90%	Local and Systemic Control	Palliation Only

3.3.5 Treatment of Recurrent Disease

When these cancers return, they usually appear in the lungs.

- For Osteosarcoma and Ewing, the focus shifts to second-line chemotherapy (e.g., Ifosfamide and Etoposide) and targeted therapies.
- For Chondrosarcoma, recurrence often requires more radical surgery, such as amputation, if the previous limb-salvage site is contaminated.
- The biological "personality" of the tumor dictates the weapons used. While a pediatric patient with Ewing sarcoma may be cured through a combination of drugs and radiation, an adult with chondrosarcoma relies almost entirely on the precision of the orthopedic oncologist's scalpel.[32,33]

CONCLUSION

The clinical management of primary bone cancers represents a complex intersection of surgical precision, pharmacological intensity, and diagnostic vigilance. While osteosarcoma, Ewing sarcoma, and chondrosarcoma remain rare, their impact on patient morbidity and mortality necessitates a rigorous, multidisciplinary approach centered on early detection via plain radiography and immediate referral to specialized centers. The transition from radical amputation to limb-salvage surgery—supported by the strategic use of neoadjuvant and adjuvant chemotherapy—has fundamentally redefined the prognosis for localized disease, achieving survival rates of nearly 80% and preserving functional quality of life. However, a significant prognostic ceiling persists for patients with metastatic involvement, where survival outcomes remain stubbornly low. Future advancements in orthopedic oncology must prioritize the identification of early biomarkers to shorten the diagnostic window and the development of targeted therapies to overcome the chemoresistance seen in chondrosarcoma and metastatic lineages. Ultimately, the successful treatment of primary bone malignancies depends not only on the eradication of the primary tumor but on the systemic control of micrometastatic disease, reinforcing the necessity of life-long surveillance and integrated oncological care.

REFERENCES

1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer, 2009; 115(7): 1531-1543.
2. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res, 2009; 152: 3-13.
3. Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018; 29(Suppl 4): iv79-iv95.
4. Rickel K, Fang F, Tao J. Molecular genetics of osteosarcoma. Bone, 2019; 121: 172-179.
5. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res, 2007; 459: 40-47.
6. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am, 2000; 82(5): 662-674.

7. Bacci G, Ferrari S, Longhi A, et al. Delay in diagnosis of high-grade osteosarcoma of the extremities. Has it any effect on the prognosis? Eur J Cancer, 2000; 36(16): 2045-2050.
8. Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology, 1997; 202(1): 237-246.
9. Ewing J. Diffuse endothelioma of bone. Proc N Y Pathol Soc, 1921; 21: 17-24. (The original description).
10. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist, 2006; 11(5): 503-519.
11. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature, 1992; 359(6391): 162-165.
12. Donaldson SS. Ewing sarcoma: Family of Tumors. Cancer, 1995; 75(S1): 327-332.
13. Giuffrida AY, Burgueno JE, Koniaris LG, et al. Chondrosarcoma of the bone: recent advances. Curr Opin Oncol, 2009; 21(4): 370-377.
14. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer, 1977; 40(2): 818-831.
15. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical management of chondrosarcoma: a continuous challenge. Eur J Cancer, 2008; 44(11): 1475-1483.
16. Angelini A, Guerra G, Trovarelli G, et al. Chondrosarcoma of the pelvis: Analysis of prognostic factors and outcomes. J Surg Oncol, 2014; 110(2): 155-162.
17. Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: presentation and outcomes of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol, 2003; 21(10): 2011-2018.
18. Briccoli A, Rocca M, Salone M, et al. High-grade osteosarcoma of the extremities: metastatic at presentation. J Clin Oncol, 2003; 21(11): 2136-2142.
19. Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenge for oncology and surgery. Future Oncol, 2016; 12(18): 2151-2163.
20. Paget S. The distribution of secondary growths in cancer of the breast. Lancet, 1889; 133(3421): 571-573. (Original "Seed and Soil" paper).
21. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res, 1986; 204: 9-24. (Seminal paper on surgical staging).
22. Lodwick GS, Wilson A, Farrell C, et al. Determining growth rates of focal lesions of bone from radiographs. Radiology, 1980; 134: 577-583.
23. van Praag Veroniek VM, Rueten-Budde AJ, Ho V, Dijkstra PDS, Study group Bone and Soft tissue tumours (WeBot). Fiocco M, van de Sande MAJ. Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surg Oncol, 2018 Sep; 27(3):402-408.
24. Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT, Gannon FH. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics, 2003 Sep-Oct; 23(5): 1245-78.
25. Desai SS, Jambhekar NA. Pathology of Ewing's sarcoma/PNET: Current opinion and emerging concepts. Indian J Orthop, 2010 Oct; 44(4): 363-8.
26. Giannoulis DK, Gantsos A, Giotis D, Paschos NK, Vagionas A, Arnaoutoglou CM, Pentheroudakis G, Xenakis

TA. Multiple recurrences and late metastasis of adamantinoma in the tibia: a case report. J Orthop Surg (Hong Kong), 2014 Dec; 22(3): 420-2.

27. Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer, 2014 Jun 15; 120(12): 1763-74.
28. Plant J, Cannon S. Diagnostic work up and recognition of primary bone tumours: a review. EFORT Open Rev, 2016 Jun; 1(6): 247-253.
29. Kundu ZS. Classification, imaging, biopsy and staging of osteosarcoma. Indian J Orthop, 2014 May; 48(3): 238-46.
30. Amit P, Patro DK, Basu D, Elangovan S, Parathasarathy V. Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas. Am J Clin Oncol, 2014 Aug; 37(4): 384-90.
31. Quartuccio N, Fox J, Kuk D, Wexler LH, Baldari S, Cistaro A, Schöder H. Pediatric bone sarcoma: diagnostic performance of ^{18}F-FDG PET/CT versus conventional imaging for initial staging and follow-up. AJR Am J Roentgenol, 2015 Jan; 204(1): 153-60.
32. Endo M, Lin PP. Surgical margins in the management of extremity soft tissue sarcoma. Chin Clin Oncol, 2018 Aug; 7(4): 37.
33. Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop, 2006 Dec; 30(6): 445-51.